Dear Partners,
2024 was a year of remarkable progress, made possible by your unwavering partnership and the resilience of our global organization.
A defining chapter of the past 12 months was our successful transition from a single operational site to multiple facilities across Israel and abroad. Forced by the realities of war, this complex move was executed with minimal interruptions to service in a true testament to our teams’ dedication, agility, and innovative spirit.
Growth was a constant theme for us. We completed the establishment of new subsidiaries in Korea, Spain, Germany, and India, along with a joint venture in France—an important step in our strategic expansion plan. Our market share for premium intraocular lenses for cataract surgery continued to rise, with the remarkable 80% growth over 2023 of our pioneering Pentafocal technology.
This year also marked the successful construction and qualification of two advanced manufacturing facilities—one in Israel, and the other in China—which will further secure our ability to meet growing global demand.
Reflecting our commitment to innovation, we were granted patents in several countries this year. Our patented technologies, including the Intensity Pentafocal IOL’s unique method and design, are securing the future of eye care by fostering solutions that deliver better vision for patients worldwide. Read more about our patents here.
Our presence at key national and international congresses, particularly the ESCRS in Barcelona, allowed us to share clinical successes and solidify relationships with the global ophthalmic community.
All our efforts paid off. Despite the unexpected and extreme circumstances that challenged the team in all business aspects, we saw a 25% sales growth over the previous year.
Building on Strength: What’s Next for 2025
Looking ahead to 2025, we are poised to build on this momentum with a renewed focus on innovation and operational excellence:
- Our new facilities in Bar Lev, Israel and Juchai, China will be fully operational, harnessing the latest manufacturing technologies to support the growing demand for our products.
- We will expand our portfolio with the Extend hydrophobic IOL, and leverage our proprietary Dynamic Light Utilization (DLU) technology with the Intensity hydrophobic IOL.
- We will advance key clinical studies in China, Japan, and India, and enhance collaboration with The David J. Apple Center for Vision Research in Heidelberg, Germany.
- Plans are underway to establish a central logistics hub in Europe, enhancing responsiveness and supporting regional partner growth.
- We are setting the foundation for new subsidiaries in Europe and North America, expanding our global footprint.
- We continue to push the boundaries of innovation to meet the ever-growing expectations for optimal refractive outcomes and spectacle independence.
The past year’s challenges have reaffirmed our commitment to excellence while our achievements continue to serve as a powerful reminder of the strength we possess when we stand together.
Thank you to our partners for being an integral part of our journey, and a special thank you to our incredible team for your unshakeable dedication. Here’s to a successful, innovative, and impactful 2025!
Warm regards,
Yoram Gonen
CEO, Hanita Lenses
